drugset / Trial / NCT04326283
Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.
Timeline
- Start
- 2020-04-02
- Primary completion
- 2023-04-28
- Completion
- 2023-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Riluzole | Small molecule | 50 mg | — |
| Subject | Trametinib | Small molecule | 0.5 mg | — |
| Subject | Trametinib | Small molecule | 1 mg | — |